Teresa Palomero
Peripheral T-cell Lymphoma
Teresa Palomero, PhD
New York, NY
United States
Columbia University Medical Center
Teresa Palomero is a Professor of Pathology and Cell Biology at Columbia University Irving Medical Center and an internationally recognized cancer researcher in the field of leukemia and lymphoma. For more than 25 years, she has studied how genetic and molecular changes cause aggressive blood cancers and how to translate this knowledge into new treatments. Her discoveries have helped define the genetic basis of several T-cell lymphomas and leukemias and identified new therapeutic targets. Her laboratory has also developed advanced mouse models to better understand disease biology and preclinical testing of precision therapies. Dr. Palomero’s work has been published in leading scientific journals and has contributed to shaping the current understanding of T-cell lymphomas, paving the way for the development of targeted therapies.
Program Name(s)
Discovery
Translational Research Program
Project Title
Targeting Microenvironment Determinants in Peripheral T-cell Lymphoma
Therapeutic Targeting of Sphingosine-1-phosphate Receptor 1 in Angioimmunoblastic T-Cell Lymphoma
Lawrence Boise
CART and myeloma
Lawrence Boise, PhD
Atlanta, GA
United States
Emory University
Lawrence Boise, PhD is the R. Randall Rollins Chair of Oncology and Professor in the Department of Hematology and Medical Oncology in the Emory University School of Medicine. Dr. Boise also serves as the Associate Director of Education and Training in the Winship Cancer Institute of Emory University. He received his PhD from VCU-Medicine and did his postdoctoral training at the University of Michigan and the University of Chicago. Dr. Boise took his first faculty position at the University of Miami in 1996 and rose to the rank of Professor before moving to Emory in 2009. Dr. Boise was involved in early studies to identify genes that control cell survival and cell death and has been studying these processes to better understand how to improve our treatment of cancer, particularly the plasma cell malignancy multiple myeloma. Dr. Boise serves as a Senior Editor at Molecular Cancer Research and is on the editorial board of Blood Cancer Discovery.
Program Name(s)
Discovery
Project Title
Michael Bern, MD, PhD
St. Louis, MO
United States
Washington University in St. Louis
Dr. Bern is a post-doctoral fellow in Dr. Timothy Ley’s lab at Washington University School of Medicine and a clinical fellow in the Hematology and Oncology program. He earned his bachelor’s degree in Physics from Duke University. Following undergraduate, he completed M.D./Ph.D. training at Washington University School of Medicine, where he earned his Ph.D. in Immunology, studying mechanisms regulating natural killer cell activation, in the laboratory of Dr. Wayne Yokoyama. He then joined the Physician Scientist Training Program at Washington University School of Medicine for Internal Medicine residency and Heme/Onc fellowship. His current research is focused on understanding mechanisms of chemotherapy resistance in Primary-Refractory Acute Myeloid Leukemia. His long-term goal is to identify novel therapeutic strategies for this population of patients with extremely poor outcomes and few treatment options.
Program Name(s)
Career Development Program
Project Title
Adam de Smith
pediatric ALL and Down Syndrome
Adam de Smith, PhD
Duarte, CA
United States
Beckman Research Institute of the City of Hope
I am a genetic epidemiologist and Associate Professor in the Department of Pediatrics at the City of Hope National Medical Center. During my PhD, my research was focused on genetic variation and its role in human disease, and I received training in genetic epidemiology. Keen to pursue a career in childhood cancer research, I obtained a postdoctoral position at UCSF studying the etiology of acute lymphoblastic leukemia (ALL), the most common childhood cancer. I held a faculty position at the University of Southern California from 2018-2025 before joining City of Hope, where I lead epidemiology studies of ALL in high-risk populations, including Hispanic/Latinos and children with Down syndrome, and investigations into the early-life origins of childhood leukemia. My research has led to several novel discoveries, identifying new risk factors for ALL and shedding light on how Down syndrome increases leukemia risk. Understanding the causes of childhood ALL is my life’s work, with the hope that our discoveries will help to develop precision prevention strategies.
Program Name(s)
Career Development Program
Project Title
Hannah Maul-Newby, PhD
New Haven, CT
United States
Yale University
I received my BS in biochemistry from Gonzaga University and my PhD in Molecular, Cell and Developmental Biology under the guidance of Dr. Melissa Jurica at UC Santa Cruz. In the Jurica lab, I studied RNA splicing, the fundamental process of removing non-coding pieces of RNA from regions which code proteins. My dissertation focused on the characterization of an RNA helicase and its role in early spliceosome assembly. Early spliceosomal proteins are commonly mutated in human diseases such as blood cancers, but until recently, scientists did not have the tools to allow for dissection of the mechanisms involved. I chose to pursue my postdoctoral training in a blood cancer lab to dive deep into the role of splicing factor mutations in myelodysplastic syndromes and leukemia. I seek to apply my expertise in RNA processing biochemistry to blood cancers with the goal to contribute to better understanding and novel therapeutic approaches.
Program Name(s)
Career Development Program
Project Title
Revisiting splicing factor mutations in MDS/AML – delving deep and wide
Meher Gayatri Bolisetti, PhD
Madison, WI
United States
University of Wisconsin at Madison
I have been interested in basic and translational work related to cancer since my master’s resulting in a thesis on bone metastasis of breast cancer. Part of my PhD work explored the molecular mechanisms of chronic myelogenous leukemia (CML). I have studied the use of metformin, as an anti-cancer agent and demonstrated that metformin through activation of AMPK/ RUNX1/ SOCS3 axis and inhibition of glycolytic fluxes overcomes the imatinib resistance in CML patients. I joined Dr. Jing Zhang’s lab at the University of Wisconsin. Under her guidance, I had a chance to explore the molecular players involved in a subset of acute myeloid leukemia (AML) with concurrent RAS and ASXL1 mutations, which define one of the worst AML prognosis groups. I have been actively collaborating with numerous investigators on and off campus to work on patient derived xenograft model for pre-clinical development of therapeutic approaches targeting both leukemia cells and suppressed T cells in NRAS; ASXL1 AML.
Project Title
Steven Park
follicular lymphoma
Steven Park, MD
Charlotte, NC
United States
Atrium Health Foundation
I am a physician scientist, specializing in lymphoma therapy. My area of research is focused on the development of new therapeutic approaches in lymphoma by engineering special nanoparticle-based drug-delivery platforms. My team has pioneered a novel high-precision drug delivery system using “click chemistry”, which is composed of high-affinity binding chemical couples. By using this novel technique, we have shown an 8-fold increase in tumor uptake of small molecule drugs compared to the conventional drug delivery, with no discernable toxicity in lymphoma models. My second major area of research involves cell signaling pathways, and their impact on lymphoma cell survival. If this novel targeted therapy platform proves successful, pretargeted nanoparticle approach can be utilized to enhance the potency and precision of small molecule drugs for treatment of relapsed mantle cell lymphoma and transformed follicular lymphoma, which are associated with chemoresistance and poor prognosis.
Program Name(s)
Translational Research Program
Project Title
Next-Generation Targeted Therapy in Mantle Cell Lymphoma and Transformed Follicular Lymphoma
Juan Alderuccio, MD
Miami, FL
United States
University of Miami
Dr. Alderuccio is the Clinical Research Site Disease Group Leader in the Lymphoma Section at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine. Dr. Alderuccio’s institutional obligations include caring for patients with lymphoma, conducting clinical and translational research, mentoring junior faculty, and overseeing the clinical trial operations of more than 30 studies. He conducts clinical trials using novel therapeutics aiming to improve outcomes in patients with aggressive lymphoma. His translational research focuses on developing decision-making models that integrate imaging, biomarkers, and clinical data using machine learning approaches. Consequently, he is an author of more than 75 peer-reviewed manuscripts and has communicated his studies at national and international meetings. Dr. Alderuccio is also a member of the American Society of Hematology, where he serves on the Communications and Educational Affairs Committees.
Program Name(s)
Career Development Program
Project Title
Novel strategies toward improving outcomes in large B-cell lymphoma
Samantha Tauchmann, PhD
Portland, OR
United States
OHSU Knight Cancer Institute
Samantha Tauchmann Ph.D. is a postdoc at the Oregon Health & Science University. She received a B.S. in Molecular Life Sciences from Maastricht University in the Netherlands and her M.Sc. in Biomedical Sciences from the Transnational University Limburg. She completed her PhD under the mentorship of Prof. Dr. Jürg Schwaller at the University Children`s Hospital Basel in Switzerland, where she investigated the role of the methyltransferase NSD1 and the key erythroid transcription factor, GATA1, in erythroleukemia. Dr. Tauchmann joined the Maxson laboratory in February 2023. Her postdoctoral studies are focused on uncovering how SETBP1 mutations contribute to leukemia by modulating the function of methyltransferases. With a strong commitment to understanding blood cell development and leukemia biology, Dr. Tauchmann aspires to identify new therapeutics for SETBP1-mutant leukemias. Her long-term goal is to run an academic laboratory focused on epigenetic dysregulation in blood cancers.
Project Title
Histone methyltransferases as key dependencies in SETBP1-mutant leukemias
Jonathon Cohen
lymphoma clinical trial access in Georgia
Jonathon Cohen, MD
Atlanta, GA
United States
Emory University
Dr. Jonathon Cohen is an associate professor of hematology/oncology at Emory University and co-directs the lymphoma program at Winship Cancer Institute. He has developed and implemented studies conducted at sites throughout the US and frequently collaborates with colleagues throughout Georgia to offer trials to patients with lymphoma. He is a member of the ECOG-ACRIN Lymphoma Core Committee, Co-Chair of the Hoosier Cancer Research Network Lymphoma Committee, and Co-Chair of the Lymphoma Disease Focus Group of the NCI-funded Experimental Therapeutics Clinical Trials Network Consortium. He also leads national studies evaluating real-world outcomes in lymphoma. He has an active clinical practice providing consultative services for patients throughout Georgia. He has routinely engaged with oncologists throughout the region to promote quality lymphoma care through in-person and virtual educational talks, and through moderation of protocol sessions to develop treatment guidelines.
Program Name(s)
IMPACT
Project Title
Making an IMPACT on hematology care in Georgia: The Georgia Blood Cancer Trials Network (BCTN)
Paul Beavis
immunotherapy in myeloma
Paul Beavis, PhD
Melbourne,
Australia
The University of Melbourne
I am an Assoc. Prof. and Group Leader at the Peter MacCallum Cancer Centre (Peter Mac; Melbourne, Australia). I formed my group in 2018 and my research program is focused upon enhancing the effectiveness of chimeric antigen receptor (CAR) T cells, a form of immune therapy where a patient’s own immune cells are genetically engineered to recognize and kill tumor cells. I have published numerous seminal papers and research metrics place me in the top 1% of researchers in my field. Despite being a PI for just 5 years, I have already led 1 CAR T clinical trial and I am currently developing a second trial with a technology developed in my lab in 2020.
Previously my focus has been on using CAR T to treat cancers such as breast and lung cancer. However, recent clinical data indicates that CAR T cells have significant potential in multiple myeloma. Therefore, this project will be a key strategic enabler, allowing me to apply approaches developed in my lab to this disease.
Program Name(s)
Translational Research Program
Project Title
Enhancing the “fitness” of anti-BCMA CAR T cells for improved efficacy in multiple myeloma
Lev Kats
myeloma and epigenetics
Lev Kats, PhD
Parkville, VIC
Australia
The University of Melbourne
Dr. Lev Kats is head of the Targeted Therapeutics Laboratory at the Peter MacCallum Cancer Centre. He completed his PhD at Monash University and postdoctoral training at Beth Israel Deaconess Centre/Harvard Medical School. Dr. Kats has made major contributions in the areas of targeted therapies, epigenetics and hematological malignancies including through discovery of important functions of cancer promoting genes and the characterization of the molecular mechanisms of anti-leukemic drugs. His laboratory uses model systems, functional and molecular genomics approaches to develop and test new therapeutic strategies for aggressive blood cancers.
Program Name(s)
Translational Research Program
Targeting DCAF1 as a novel treatment strategy for therapy resistant multiple myeloma